These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8223830)

  • 1. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
    Wolffenbuttel BH; Nijst L; Sels JP; Menheere PP; Müller PG; Kruseman AC
    Eur J Clin Pharmacol; 1993; 45(2):113-6. PubMed ID: 8223830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
    Landgraf R; Bilo HJ; Müller PG
    Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
    Mafauzy M
    Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide versus glyburide: a one-year comparison trial.
    Marbury T; Huang WC; Strange P; Lebovitz H
    Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide as monotherapy in Type 2 diabetes.
    Gomis R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR; Jarvis B
    Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
    Wolffenbuttel BH
    Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
    Esposito K; Giugliano D; Nappo F; Marfella R;
    Circulation; 2004 Jul; 110(2):214-9. PubMed ID: 15197140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.